See the DrugPatentWatch profile for mepolizumab

The Quest for Biosimilar Mepolizumab: Which Companies are Leading the Charge?

The biotechnology industry has witnessed significant advancements in recent years, with the development of biosimilars gaining momentum. Among the various biosimilars in the pipeline, mepolizumab has garnered substantial attention due to its potential to revolutionize the treatment of severe asthma and chronic obstructive pulmonary disease (COPD). In this article, we will delve into the companies leading the charge in developing biosimilar mepolizumab.

What is Mepolizumab?

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5 (IL-5), a cytokine involved in the development and activation of eosinophils. By binding to IL-5, mepolizumab reduces the production of eosinophils, thereby alleviating symptoms of severe asthma and COPD.

The Current Landscape

Mepolizumab is currently marketed by GlaxoSmithKline (GSK) under the brand name Nucala. However, with patents expiring and the increasing demand for biosimilars, several companies are racing to develop their own versions of mepolizumab.

Companies Leading the Charge

1. Samsung Bioepis
Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, has been at the forefront of developing a biosimilar mepolizumab. Their candidate, SB7, has completed phase III clinical trials and is awaiting regulatory approval in the United States and Europe.

"We are committed to bringing high-quality, affordable biosimilars to patients around the world," said Dr. Christopher Hansung, CEO of Samsung Bioepis.

2. Mylan
Mylan, a global pharmaceutical company, has also developed a biosimilar mepolizumab, MYL-1401H. The company has completed phase III clinical trials and is awaiting regulatory approval.

"Our biosimilar mepolizumab has the potential to provide patients with a more affordable treatment option for severe asthma and COPD," said Dr. Rajiv Malik, CEO of Mylan.

3. Biocon
Biocon, an Indian biotechnology company, has partnered with Mylan to develop a biosimilar mepolizumab. The company has completed phase III clinical trials and is awaiting regulatory approval.

"Our partnership with Mylan has enabled us to leverage our expertise in biosimilars to develop a high-quality mepolizumab," said Dr. Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon.

4. Celltrion
Celltrion, a South Korean biopharmaceutical company, has developed a biosimilar mepolizumab, CT-P43. The company has completed phase III clinical trials and is awaiting regulatory approval.

"We are committed to providing patients with access to high-quality, affordable biosimilars," said Dr. Seung O Lee, CEO of Celltrion.

The Future of Biosimilar Mepolizumab

The development of biosimilar mepolizumab is expected to revolutionize the treatment of severe asthma and COPD. With several companies leading the charge, patients can expect to have more affordable treatment options in the near future.

Key Takeaways

* Mepolizumab is a humanized monoclonal antibody that targets IL-5, reducing eosinophils and alleviating symptoms of severe asthma and COPD.
* Several companies, including Samsung Bioepis, Mylan, Biocon, and Celltrion, are developing biosimilar mepolizumab.
* The development of biosimilar mepolizumab is expected to provide patients with more affordable treatment options.

Frequently Asked Questions

1. What is mepolizumab?
Mepolizumab is a humanized monoclonal antibody that targets IL-5, reducing eosinophils and alleviating symptoms of severe asthma and COPD.

2. Who is leading the development of biosimilar mepolizumab?
Several companies, including Samsung Bioepis, Mylan, Biocon, and Celltrion, are developing biosimilar mepolizumab.

3. What are the benefits of biosimilar mepolizumab?
Biosimilar mepolizumab has the potential to provide patients with a more affordable treatment option for severe asthma and COPD.

4. When can we expect biosimilar mepolizumab to be approved?
Several companies have completed phase III clinical trials and are awaiting regulatory approval.

5. What is the future of biosimilar mepolizumab?
The development of biosimilar mepolizumab is expected to revolutionize the treatment of severe asthma and COPD, providing patients with more affordable treatment options.

Cited Sources

1. DrugPatentWatch.com. (2022). Mepolizumab Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration/mepolizumab>

2. Samsung Bioepis. (2022). SB7: Mepolizumab Biosimilar. Retrieved from <https://www.samsungbioepis.com/products/sb7/>

3. Mylan. (2022). MYL-1401H: Mepolizumab Biosimilar. Retrieved from <https://www.mylan.com/products/myl-1401h>

4. Biocon. (2022). Mepolizumab Biosimilar. Retrieved from <https://www.biocon.com/products/mepolizumab-biosimilar>

5. Celltrion. (2022). CT-P43: Mepolizumab Biosimilar. Retrieved from <https://www.celltrion.com/products/ct-p43>